Eli Lilly (LLY) Announces Expanded Indication for ALIMTA in Certain Lung Cancers

Eli Lilly and Company (NYSE: LLY) announced today that patients may receive ALIMTA (pemetrexed for injection) as a maintenance therapy following first-line ALIMTA plus cisplatin for locally advanced or metastatic nonsquamous non-small cell lung cancer (NS NSCLC). The FDA approved the label inclusion of Phase III data that demonstrated progression-free and overall survival advantages in the continuation maintenance setting for these patients.

Appropriate patients can now start with ALIMTA plus cisplatin and continue with ALIMTA in the maintenance setting in advanced or metastatic NS NSCLC. ALIMTA is indicated for the maintenance treatment of patients with locally advanced or metastatic NS NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. ALIMTA is not indicated for patients with squamous-cell NSCLC. Myelosuppression is usually the dose-limiting toxicity with ALIMTA therapy.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Amplitude Therapeutics signs taRNA vaccine deal with Eli Lilly
• Boeing names Ryan Shedd as new SVP and controller
• Home Depot expands executive roles, grants $500K in restricted stock